Stay updated on Nivolumab in Refractory Biliary Tract Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.

Latest updates to the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page
- CheckyesterdayChange DetectedThe page shows updated study record dates, including the last update and results posting dates. Core study details such as completion status and locations appear current.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check30 days agoChange Detected- Added a government funding lapse notice and operating status details for the NIH Clinical Center, plus a link to relevant official sites. - Upgraded version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check37 days agoChange DetectedThe page updates its metadata to reflect a newer version (v3.1.0) and more recent dates (September 2025), while removing older metadata (v3.0.2 and May 2025 dates).SummaryDifference0.7%

- Check51 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' control was removed. No substantive changes to core content, pricing, names, stock, or time slot availability.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%

- Check66 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new medical topics related to digestive diseases and proteins. However, several previous entries, including specific cancer-related terms and immunological agents, have been removed.SummaryDifference3%

Stay in the know with updates to Nivolumab in Refractory Biliary Tract Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.